RATIONALE: Hallucinogenic serotonin 2A (5-HT(2A)) receptor partial agonists, such as (+ or -)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane hydrochloride (DOI), induce a frontal cortex-dependent head-twitch response (HTR) in rodents, a behavioral proxy of a hallucinogenic response that is blocked by 5-HT(2A) receptor antagonists. In addition to 5-HT(2A) receptors, DOI and most other serotonin-like hallucinogens have high affinity and potency as partial agonists at 5-HT(2C) receptors. OBJECTIVES: We tested for involvement of 5-HT(2C) receptors in the HTR induced by DOI. RESULTS: Comparison of 5-HT(2C) receptor knockout and wild-type littermates revealed an approximately 50% reduction in DOI-induced HTR in knockout mice. Also, pretreatment with either the 5-HT(2C) receptor antagonist SB206553 or SB242084 eradicated a twofold difference in DOI-induced HTR between the standard inbred mouse strains C57BL/6J and DBA/2J, and decreased the DOI-induced HTR by at least 50% in both strains. None of several measures of 5-HT(2A) receptors in frontal cortex explained the strain difference, including 5-HT(2A) receptor density, Galpha(q) or Galpha(i/o) protein levels, phospholipase C activity, or DOI-induced expression of Egr1 and Egr2. 5-HT(2C) receptor density in the brains of C57BL/6J and DBA/2J was also equivalent, suggesting that 5-HT(2C) receptor-mediated intracellular signaling or other physiological modulators of the HTR may explain the strain difference in response to DOI. CONCLUSIONS: We conclude that the HTR to DOI in mice is strongly modulated by 5-HT(2C) receptor activity. This novel finding invites reassessment of hallucinogenic mechanisms involving 5-HT(2) receptors.
RATIONALE: Hallucinogenic serotonin 2A (5-HT(2A)) receptor partial agonists, such as (+ or -)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane hydrochloride (DOI), induce a frontal cortex-dependent head-twitch response (HTR) in rodents, a behavioral proxy of a hallucinogenic response that is blocked by 5-HT(2A) receptor antagonists. In addition to 5-HT(2A) receptors, DOI and most other serotonin-like hallucinogens have high affinity and potency as partial agonists at 5-HT(2C) receptors. OBJECTIVES: We tested for involvement of 5-HT(2C) receptors in the HTR induced by DOI. RESULTS: Comparison of 5-HT(2C) receptor knockout and wild-type littermates revealed an approximately 50% reduction in DOI-induced HTR in knockout mice. Also, pretreatment with either the 5-HT(2C) receptor antagonist SB206553 or SB242084 eradicated a twofold difference in DOI-induced HTR between the standard inbred mouse strains C57BL/6J and DBA/2J, and decreased the DOI-induced HTR by at least 50% in both strains. None of several measures of 5-HT(2A) receptors in frontal cortex explained the strain difference, including 5-HT(2A) receptor density, Galpha(q) or Galpha(i/o) protein levels, phospholipase C activity, or DOI-induced expression of Egr1 and Egr2. 5-HT(2C) receptor density in the brains of C57BL/6J and DBA/2J was also equivalent, suggesting that 5-HT(2C) receptor-mediated intracellular signaling or other physiological modulators of the HTR may explain the strain difference in response to DOI. CONCLUSIONS: We conclude that the HTR to DOI in mice is strongly modulated by 5-HT(2C) receptor activity. This novel finding invites reassessment of hallucinogenic mechanisms involving 5-HT(2) receptors.
Authors: K J Damjanoska; B A Heidenreich; G H Kindel; D N D'Souza; Y Zhang; F Garcia; G Battaglia; W A Wolf; L D Van de Kar; N A Muma Journal: J Pharmacol Exp Ther Date: 2004-02-19 Impact factor: 4.030
Authors: Juan F López-Giménez; Laurence H Tecott; José M Palacios; Guadalupe Mengod; M Teresa Vilaró Journal: J Neurosci Res Date: 2002-01-01 Impact factor: 4.164
Authors: S P Vickers; N Easton; C S Malcolm; N H Allen; R H Porter; M J Bickerdike; G A Kennett Journal: Pharmacol Biochem Behav Date: 2001 Jul-Aug Impact factor: 3.533
Authors: A Gobert; J M Rivet; F Lejeune; A Newman-Tancredi; A Adhumeau-Auclair; J P Nicolas; L Cistarelli; C Melon; M J Millan Journal: Synapse Date: 2000-06-01 Impact factor: 2.562
Authors: Philippe De Deurwaerdère; Sylvia Navailles; Kelly A Berg; William P Clarke; Umberto Spampinato Journal: J Neurosci Date: 2004-03-31 Impact factor: 6.167
Authors: Boris B Quednow; Anne Schmechtig; Ulrich Ettinger; Nadine Petrovsky; David A Collier; Franz X Vollenweider; Michael Wagner; Veena Kumari Journal: Biol Psychiatry Date: 2009-06-28 Impact factor: 13.382
Authors: Claudia Rangel-Barajas; Ana María Estrada-Sánchez; Scott J Barton; Robert R Luedtke; George V Rebec Journal: Neuropharmacology Date: 2016-11-02 Impact factor: 5.250
Authors: Jeremy M Veenstra-Vanderweele; Aurelio Galli; Christine Saunders; Michael Siuta; Sabrina D Robertson; Adeola R Davis; Jennifer Sauer; Heinrich J G Matthies; Paul J Gresch; David Airey; Craig W Lindsley; John A Schetz; Kevin D Niswender Journal: Neurochem Int Date: 2013-09-30 Impact factor: 3.921